Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Gains from Investment Securities (2016 - 2026)

Catalyst Pharmaceuticals filings provide 16 years of Gains from Investment Securities readings, the most recent being $12.4 million for Q1 2026.

  • On a quarterly basis, Gains from Investment Securities rose 2333.51% to $12.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $12.4 million, a 2333.51% increase, with the full-year FY2025 number at $12.2 million, down 6.91% from a year prior.
  • Gains from Investment Securities hit $12.4 million in Q1 2026 for Catalyst Pharmaceuticals, up from $912000.0 in the prior quarter.
  • In the past five years, Gains from Investment Securities ranged from a high of $31.1 million in Q4 2022 to a low of $35693.0 in Q1 2024.
  • Median Gains from Investment Securities over the past 5 years was $633000.0 (2022), compared with a mean of $6.2 million.
  • Biggest five-year swings in Gains from Investment Securities: tumbled 97.87% in 2024 and later surged 34015.98% in 2025.
  • Catalyst Pharmaceuticals' Gains from Investment Securities stood at $31.1 million in 2022, then plummeted by 30.15% to $21.7 million in 2023, then tumbled by 97.87% to $464000.0 in 2024, then soared by 96.55% to $912000.0 in 2025, then surged by 1263.4% to $12.4 million in 2026.
  • The last three reported values for Gains from Investment Securities were $12.4 million (Q1 2026), $912000.0 (Q4 2025), and $11.3 million (Q3 2025) per Business Quant data.